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Background: Hepatic epithelioid haemangioendothelioma (HEH) is a rare vascular neoplasm with
unpredictable clinical behaviour.
Aim: To compare overall survival (OS) and disease-free survival (DFS) between liver resection (LR) and
orthotopic liver transplantation (OLT) for the treatment of HEH.
Methods: Retrospective review of 30 patients with HEH treated at Mayo Clinic during 1984 and 2007.
Results: Median age was 46 years with a female predominance of 2 : 1. Treatment included LR (n = 11),
OLT (n = 11), chemotherapy (n = 5) and no treatment (n = 3). LR was associated with a 1-, 3- and 5-year
OS of 100%, 86% and 86% and a DFS of 78%, 62% and 62%, respectively. OLT was associated with
a 1-, 3- and 5-year OS of 91%, 73% and 73% and a DFS 64%, 46% and 46%, respectively. Metastases
were present in 37% of patients but did not significantly affect OS. Important predictors of a favourable
OS and DFS were largest tumour  10 cm and multifocal disease with 10 nodules.
Conclusion: LR and OLT achieve comparable results in the treatment of HEH. LR is appropriate for
patients with resectable disease and favourable prognostic factors. OLT is appropriate for patients with
unresectable disease and possibly those with unfavourable prognostic factors. Metastases may not be a
contraindication to surgical treatment.
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Introduction
Hepatic epithelioid haemangioendothelioma (HEH) is a rare vas-
cular neoplasm accounting for less than 1% of all hepatic malig-
nancies.1 Since initially described in 1982 by Weiss and Enzinger,2
less than 500 cases have been reported.3 HEH primarily occurs in
women in the mid fifth decade of life without underlying chronic
liver disease. Aetiologic risk factors are unknown, although HEH
has occurred in association with oral contraceptive pills (OCPs),
exposure to vinyl chloride or major hepatic trauma.3–7 Clinical
presentation is variable and non-specific and ranges from an
indolent course6,7 to a rapidly progressive disease.8–12 In nearly
25% of patients, HEH is diagnosed incidentally. The diagnosis of
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HEH is confirmed by immunostaining for factor VIII-related
antigens and other endothelial markers on biopsy.2 No imaging
features of HEH are pathognomonic.
The optimal treatment for HEH is disputed. In fact, all current
treatment recommendations are based on evidence from limited
retrospective clinical series. Moreover, treatment is influenced by
the clinical behaviour of the HEH encountered, and the practice
expertise of the managing surgeons or physicians. Although both
liver resection (LR) and orthoptic liver transplantation (OLT)
have been used as treatment options, neither has proven superior.
Initial reports of LR were disappointing with a 5-year survival of
only 28%.6 Outcome after OLT is reportedly better than LR with a
5-year survival of 64%;13 however, whether this clinical difference
is attributable to OLT as a more optimal treatment, patient selec-
tion bias or biological behaviour of the HEH is unknown. More-
over, the lack of underlying liver disease and the extent of
intrahepatic disease also impact the recommendation of OLT for
HEH.
We reviewed our experience to further document outcomes of
both LR and OLT in the treatment of HEH.We sought to provide
additional data on outcomes for both surgical options, define
selection factors for surgical treatment and determine whether
any clinicopathological features of HEH have prognostic value.
Methods
Between 1984 and 2007, 33 consecutive adult patients with HEH
were evaluated and treated at theMayo Clinic. Three patients were
lost to follow-up and were excluded from the analysis. Of the
remaining 30 patients, four patients were treated at Mayo Clinic
Arizona; five patients were treated at Mayo Clinic Florida; and the
remaining 21 patients were treated at Mayo Clinic in Rochester,
Minnesota. We retrospectively reviewed their medical records,
radiological studies, laboratory values, operative reports and
pathological specimens.
The diagnosis of HEH in all patients was based on positive
staining for factor VIII-related antigen and other endothelial cell
markers as described by Ishak et al.6 When patients were referred
from other institutions, the liver biopsy was reviewed for patho-
logical confirmation. Ultrasonography (US), computed tomogra-
phy (CT) and magnetic resonance imaging (MRI) were reviewed
to determine site, number and size of HEH. Chest X-ray (CXR),
positron emission tomography (PET) and CT were used to detect
distant metastases.
Hepatic epithelioid hemangioendothelioma burden was
divided into groups based on number and size of nodules: 10
nodules and >10 nodules, largest HEH size <5 cm, 5–10 cm and
>10 cm. The intrahepatic morphology of HEH was classified as
nodular if masses were discreet and well circumscribed or diffuse
if masses were widespread and coalescing. The type of LR and
tumour location was classified according to the International
Hepato-Pancreato-Biliary Association (IHPBA) classification.7
Post-operative mortality and morbidity were defined at 30 days or
during the hospitalization of the incident operation. The severity
of post-operative complications was categorized according to the
Clavien et al. classification.14
A follow-up survey was mailed to 23 patients, who did not have
follow-up within the past 6 months, and 12 (52%) responded. The
follow-up survey addressed current symptoms, disease status, fre-
quency of follow-up and additional treatments rendered outside
of Mayo Clinic. Patients who chose to follow-up at the Mayo
Clinic were assessed by clinical and radiological examination.
Frequency distribution among groups was determined using
the c2-test. Survival was estimated by Kaplan–Maier. Cox propor-
tional hazards regression model was used to identify risk. A
P-value of <0.05 was considered statistically significant.
Results
Demographics
There were 30 patients with a 2:1 female-to-male ratio. The
median age was 46 years (range 21–79) (Table 1). Of the three
treatment groups, 37% (n = 11) of patients underwent LR, 37% (n
= 11) underwent OLT and the remaining 27% (n = 8) were treated
non-operatively: chemotherapy in five and no treatment in three.
The most common symptom at time of diagnosis was right upper
quadrant pain (67%). Two patients presented with liver failure,
both were secondary to Budd–Chiari syndrome. Twenty-seven per
cent of patients were completely asymptomatic and the diagnosis
was made incidentally during imaging for other indications. None
of our patients had underlying chronic liver disease, cirrhosis,
hepatic trauma or known exposure to vinyl chloride or contra-
ceptive hormones.
A pre-operative biopsy was obtained in 28 patients (93%); two
(7%) patients were diagnosed at time of resection. Consequently,
interval from diagnosis to treatment was quite disparate with a
median of 368 days (range 0–7300 days). One patient initially had
no treatment after diagnosis until disease progression prompted
treatment 20 years later. Patients with available tests for tumour
markers including alpha-fetoprotein (AFP), carcinoembryonic
antigen (CEA), cancer antigen 19-9 (CA 19-9), revealed that all
were within normal limits. Alkaline phosphatase was the most
frequent abnormal pre-operative laboratory value and was con-
sistently increased in 63% (n = 19) of patients.
Pre-operative imaging included CT in all patients, US in 50%,
MRI in 40% and PET in 20%. Disease burden was based on
imaging and was extremely variable. Patients were divided equally
between groups with regard to number of HEH nodules, 50% had
10 nodules and 50% had >10 nodules. The largest HEH was
<5 cm in 43% of patients, between 5 and 10 cm in 30% and
>10 cm in 27%. Extrahepatic metastatic disease was present at
diagnosis in 37% of patients; however, this did not have a signifi-
cant impact on overall survival (OS) (P = 0.5). The sites of
metastases included: lung (n = 8), peritoneum (n = 2), bone (n =
2), brain (n = 1) and skin (n = 1).Multiple sites of metastases were
present in one-third of patients who had metastatic disease.
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Post-operative complications
Complications after LR occurred in 36% of patients. One patient
had a grade IV complication (perihepatic abscess requiring opera-
tive drainage). Median post-operative hospitalization was 6 days
(range: 2–15 days) after LR. Complications after OLT occurred in
54% of patients. There were three grade IV complications which
included a portal vein thrombosis, hepatic artery thrombosis
requiring thrombectomy and anastomotic revision and post-
operative bleeding requiring operative exploration and evacua-
tion of a haematoma. The last patient subsequently developed a
small bowel obstruction from an internal hernia that necessitated
re-exploration and repair of a mesenteric defect. One patient died
post-operatively (grade V complication) in a hospice on post-
operative day 16 after OLT was aborted as a result of diffuse
intraperitoneal metastases. Median post-operative hospitalization
was 19 days (range: 4–120 days) after OLT but not significantly
longer than LR (P = 0.095).
Overall survival
Overall median follow-up from time of diagnosis was 41.6
months (range 0–243 months). Overall survival for all patients
at 5 years was 64% (95% CI: 47.6-86.3%). Overall, 12 out of the
30 (40%) patients died during follow-up: one patient died
within 2 years of LR, six patients died from 1 month to 11 years
after OLT and five of the eight patients who received no treat-
ment died within 4 years of diagnosis. Interval from treatment
to death was 0.5 to 11 years after OLT. Death in the no treatment
group occurred within 1 month to 4 years after diagnosis. The
early death in the OLT treatment group was as a result of brain
metastases that were undiagnosed at the time of transplantation.
Regardless of treatment, almost all the patients who are
deceased had more than 10 tumour nodules and a diffuse
disease pattern.
Of the surviving patients, the disease status at last follow-up
was no evidence of disease (NED) in 68%, stable disease in 26%
and progressive disease in 5%. There was no significant difference
in OS (P = 0.128) after LR and OLT (Fig. 1). In the LR group,
overall survival at 1-, 3- and 5-years was 100%, 86% and 86%,
respectively. Among patients treated with OLT, overall survival at
1-, 3- and 5-years was 91%, 73% and 73%, respectively. In con-
trast, OS for patients who had medical or no treatment at 1-, 3-
and 5-years was 57%, 43% and 29%, respectively. The long-term
survival (10 years) for LR and OLT was 85.7% and 42.4%,
respectively.
Disease-free survival
There was no significant difference in disease-free survival (DFS)
after LR and OLT (P = 0.405). Disease-free survival at 1-, 3- and
5-years was 78%, 62% and 62% after LR and 64%, 46% and 46%
after OLT (Fig. 2). Forty per cent of patients underwent a subse-
quent intervention for recurrence after initial LR and OLT. Inter-
ventions included chemotherapy, radiofrequency ablation (RFA),
Table 1 Demographics and presentation
Resection
(n = 11)
Transplant
(n = 11)
Palliative
treatment (n = 8)
Total
(n = 30)
P-value
Gender 0.6955a
Female 6 (54%) 8 (77%) 6 (75%) 20 (67%)
Male 5 (45%) 3 (27%) 2 (25%) 10 (33%)
Age at diagnosis 0.0782b
Mean 40.1 46.9 52.2 45.8
Size of largest nodule at initial surgery 0.0065ac
0–10 cm 11 (100%) 8 (73%) 3 (37%) 22 (73%)
>10 cm 0 (0%) 3 (27%) 5 (62%) 8 (27%)
Number of nodules at initial surgery 0.0039acd
10 10 (91%) 3 (27%) 2 (25%) 15 (50%)
>10 1 (9%) 8 (73%) 6 (75%) 15 (50%)
Number of segments involved 0.0096acd
4 8 (73%) 2 (18%) 1 (12%) 11 (37%)
>4 3 (27%) 9 (82%) 7 (87%) 19 (63%)
Extrahepatic involvement at initial surgery 0.0031ace
N 9 (82%) 9 (82%) 1 (12%) 19 (63%)
Y 2 (18%) 2 (18%) 7 (87%) 11 (37%)
aFisher's exact.
bKruskal–Wallis.
cSignificant difference observed in a pair-wise comparison between resection and palliative treatment.
dSignificant difference observed in a pair-wise comparison between transplant and resection.
eSignificant difference observed in a pair-wise comparison between transplant and palliative treatment.
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repeat LR and extrahepatic metastasectomy. There was no differ-
ence in number of subsequent interventions between LR (n = 4)
and OLT (n = 5).
Clinicopathological factors as prognosticators
Several pathological and morphological features of HEH corre-
lated with survival (Table 2, Fig. 3a–d). Largest HEH size 10 cm
(P = 0.003) and nodular disease pattern (P = 0.01) were associated
with prolonged DFS. Number of tumour nodules 10
approached significance (P = 0.052) for prolonged DFS. Clinico-
pathological factors associated with prolonged OS were tumour
size  10 cm, 10 nodules and nodular disease 4 hepatic seg-
ments (P < 0.02). Using a univariate Cox Proportional Hazard
model, the hazard ratio (HR) for mortality in patients for >10
nodules was 5.83 (1.27–26.80, P = 0.023) and the HR for HEH
>10 cm was 10.976 (2.76–43.68, P = 0.0007). The HR for diffuse
disease pattern was 8.14 (1.75–37.91, P = 0.0076) and that for >4
liver segments involvement was 4.92 (1.06–22.77, P = 0.041)
(Table 1).
The clinicopathological factors were unevenly distributed
across the three treatment groups. Patients who underwent LR
had significantly fewer tumour nodules and liver segments
involved with HEH compared with those that underwent OLT (P
= 0.004). Patients who had extrahepatic disease had more tumour
nodules, large tumour nodules and more liver segments involved
and were more likely to receive no treatment at all (P < 0.009).
Discussion
In the present study, we sought to determine the appropriate roles
for LR and OLT in the treatment of patients with HEH. In addi-
tion, we aimed to define clinicopathological characteristics that
lead to favourable outcomes.We identified size 10 cm, number
10 and extent of hepatic involvement  4 segments as associ-
ated with prolonged DFS. Moreover, our study suggests that
patients with these findings are candidates for LR rather thanOLT;
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Figure 1 Kaplan–Meier curve demonstrating overall survival
among treatment groups. LR, liver resection; OLT, orthotopic liver
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Figure 2 Kaplan–Meier curve demonstrating disease-free survival
among treatment groups. LR, liver resection; OLT, orthotopic liver
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Table 2 Correlation of clinicopathological factors to overall survival
Variable Survival – years (%)
1 3 5 P value
Treatment option 0.1
Transplant 91 73 73
Resection 100 86 86
Palliative 57 43 29
Metastasis at diagnosis 0.5
Yes 70 50 50
No 94 80 73
Number of nodules 0.01
10 100 91 91
>10 73 51 44
Size of nodules 0.0001
<5 100 89 89
5–10 100 87 87
>10 50 25 12.5
Disease type 0.0015
Nodular 100 92 92
Diffuse 67 42 33
Hepatic segments involved 0.02
4 100 90 90
>4 75 55 48
HPB 549
HPB 2010, 12, 546–553 © 2010 International Hepato-Pancreato-Biliary Association
thus, further clarifying which operative approach should be uti-
lized in patients with HEH. Also our study reaffirmed the wide
spectrum of biological behaviour of HEH which can affect
reported outcomes and emphasized the need to further identify
better markers of its diverse tumour biology.
We identified clinicopathological factors that can stratify
patients prognostically. These factors, if confirmed, potentially
can direct therapeutic approaches and provide clinicians with
prognostic information to consult individual patients regarding
management of HEH which has variable tumour biology. The
gross pathological features of HEH which correlated with clinical
behaviour (or manifestations) included: tumour size, number of
nodules, disease type and number of hepatic segments. Survival
by largest tumour size for patients with HEH < 5 cm and 5–10 cm
was similar with 1-, 3- and 5-year OS rates of 100%, 89% and 89%
and 100%, 88% and 88%, respectively. Survival for patients with
HEH > 10 cm had significantly less OS with 1-, 3- and 5-year
survival of 5%, 25% and 13%. Therefore, patients were dichoto-
mized by largest tumour size of 10 cm and >10 cm. We also
showed that >10 HEH nodules, diffuse intrahepatic morphology
and >4 segments involvement was associated with a significantly
poorer DFS and OS. Interestingly, extrahepatic metastasis at the
time of diagnosis was not associated with a worse overall survival
and in fact two of the three patients with extrahepatic metastasis
are alive at 3 and 10 years after operative resection.
A recent review of the literature has suggested that LR can play
an important role in the treatment of patients with localized uni-
lobar HEH.3 Liver resection was not widely recommended for
patients with bilobar or infiltrating HEH because such disease
was viewed as biologically aggressive based on the frequency of
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recurrence.15 Consequently, OLT was recommended to address
bilobar HEH despite the absence of underlying cirrhosis, a
limited donor pool and the potential sequelae of long-term
immunosuppression.3,15–17 Indeed, the recommendation of OLT
for HEH is somewhat confounding given the findings that
patients undergoing OLT for HEH have more advanced intrahe-
patic disease and occasionally even extrahepatic HEH which is
distinctly disparate from the recommendations for OLT for less
advanced hepatocellular carcinoma (HCC) as evident by the
Milan (or even extended Milan) criteria used for HCC. The fact
that OLT can provide prolonged survival for advanced intrahe-
patic HEH likely implies that intrahepatic morphology or extent
of HEH does not fully reflect aggressive systemic tumour biology.
Indeed, our findings and others6,7 of prolonged survival of
patients with HEH regardless of treatment show that the natural
history of HEH is variable and, in part, has biased reported out-
comes. Regardless of unknown factors affecting natural history,
our findings support LR for HEH despite the presence of bilobar
disease. We found that the overall 5-year survival after LR and
OLT was similar (86% and 64%, respectively). Furthermore, we
found similar 1- and 5-year DFS after LR (78%, and 62%) and
OLT (64% and 46%). Thus, LR is a surgical option for many
patients with HEH regardless of bilobar distribution provided the
hepatic disease can be resected. Clearly, LR is not applicable for all
patients with HEH, and OLT will remain an important treatment
alternative. Our patients who underwent OLT had significantly
more nodules of HEH and hepatic segments involved (Table 2).
Both number of HEH nodules and involved hepatic segments
were important predictors of resectability of our patients. We
believe that OLT is a more appropriate treatment for patients with
>10 nodules or >4 involved hepatic segments. Thus, careful assess-
ment of patients pre-operatively for these findings may provide
more reliable criteria for selecting surgical approach and achiev-
ing similar oncological outcomes.
Moreover, the two patient populations treated with LR andOLT
are not similar, as our patients who underwent OLT had signifi-
cantly more nodules of HEH and hepatic segments involved
(Table 2). All of the patients treated with OLT who are deceased
had diffuse disease and either > 10 nodules, largest nodule > 10 cm
or both. Both OLT patients with favourable prognostic factors
(10 nodules,10 cm, and nodular disease) are alive with NED
at a minimum of 5 years. The more advanced disease in the OLT
patients may explain the slightly worse, although not statistically
significant, OS and DFS compared with LR.
Extrahepatic HEH at presentation occurred in 37% of our
patients and is consistent with the literature.3 However, our find-
ings and that of several others3,15,18,19 suggest that metastatic
disease is not associated with a decreased OS. Although a recent
study did find that extrahepatic disease decreased median survival
from 202 months to 59 months, none of these patients reportedly
underwent systemic chemotherapy or metastasectomy.20 All of
our patients with extrahepatic disease had some systemic chemo-
therapy and/or metastasectomy, although chemotherapy was not
associated with improved survival (P = 0.42). One (9% of all OLT
patients) patient with stable biopsy proven bilateral lung
metastases and favourable tumour factors (size, number of
nodules, and liver segments) was offered transplantation and is
currently alive with stable pulmonary metastasis 10 years later.
Two (18% of all LR patients) other patients, one withmetastasis to
the skin and the other with metastases to the skin and lung were
offered resection. The former did well and is alive without evi-
dence of disease 3 years after resection of primary and metastasis,
and the latter died just over a year after surgery. It is unclear why
metastatic HEH is not the harbinger of imminent demise that is so
often observed in other hepatic and biliary malignancies. The
biology of metastatic HEH more closely resembles neuroendo-
crine tumours where patients have stable metastatic disease for
years. Given the heterogeneity of the disease future studies are
needed to determine the underlying biology that is the cause of
this clinical observation. Given the current data we believe that
limited and stable extrahepatic disease should not be a contrain-
dication to LR or OLT, in very selected patients, particularly when
extrahepatic disease is resectable. Most patients in our study
with extrahepatic disease underwent adjunctive chemotherapy.
Chemotherapeutic agents included: doxorubicin, ifosfamide,
interferon-alpha, bevacizumab, gemcitabine, carboplatin, doc-
etaxel and paclitaxel. A complete or partial response was not
observed in any patients receiving chemotherapy.As a result of the
variability of agents and regimens of chemotherapy used, we
cannot currently recommend chemotherapy. Collaborative multi-
institutional studies would be required.
Despite numerous case series of HEH, no prognostic clinical or
histopathological features have been identified to reliably stage or
predict tumour aggressiveness. Traditional indicators of biological
activity, such as mitotic rate, nuclear atypia and capsular penetra-
tion are unrelated to outcome.7 Even distant metastases have not
consistently correlated with survival.3 This discordance among
biology and clinical outcome has made it difficult to construct
treatment algorithms and assess treatment efficacy. In addition,
the natural history of HEH is quite heterogeneous. Although the
natural history of patients with untreated HEH is typically poor
with only a 5%, 5-year survival,3 long-term survival without treat-
ment has been reported6,7,21 as evident by one of our patients who
survived over 20 years with stable disease before progression
prompted treatment. Finally, no staging system for HEH exists,
thus, comparisons of outcomes between series with different
treatment approaches are difficult.We have proposed that indica-
tors of tumour burden could be used to stage HEH: largest
tumour size, number of tumours, number of hepatic segments
involved and pattern of disease. These factors can predict prog-
nosis as well as direct surgical treatment. Selection of surgical
approaches based on the above may allow development of a
staged-based treatment approach in the future.
In conclusion, HEH remains an uncommon hepatic malig-
nancy with a varied clinical presentation and natural history.6,7,21
Consequently, a single therapeutic approach for all patients with
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HEH is not appropriate. Although usually distributed multicen-
trically in the liver, partial hepatic resection clearly can result in
long-term survival. We believe that both partial hepatectomy and
liver transplantation are selectively warranted by both our results
and others3,7,22,23 Fig. 4. HEH size, number and extent in the liver
can be used for selection of treatment for patients. Conversely, the
presence of metastasis should not be used to exclude patients from
surgical management, both LR and OLT. Finally, further studies,
ideally using a large prospective multicenter database, to corrobo-
rate our findings and to more clearly define tumour stage, predic-
tors of survival, outcomes after resection of disease in patients
with extrahepatic metastasis and natural history are urgently
needed.
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Figure 4 Suggested therapeutic strategy in patients with hepatic epithelioid haemangioendothelioma
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